ERBB2 and neoplasm: No basal-like breast tumours were ER positive, and most HER2-enriched breast tumours showed HER2 over-expression and were clinically ER negative, whereas, only two-thirds of tumours that showed ER negativity/HER2 over-expression were predicted as HER2-enriched molecular subtype.